Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANI Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PRINCETON, N.J., JAN. 06, 2026 (GLOBE NEWSWIRE) -- ANI PHARMACEUTICALS, INC. (ANI OR THE COMPANY) (NASDAQ: ANIP) TODAY ANNOUNCED THAT NIKHIL LALWANI, CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE 44TH ANNUALJ.P. MORGAN HEALTHCARE CONFERENCE ON TUESDAY, JANUARY 13, 2026, AT 3:00 P.M. PT / 6:00 P.M. ET.

ANI PHARMACEUTICALS TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

EXPERT RETINA AND UVEITIS SPECIALISTS WILL HELP SUPPORT THE GROWTH AND INNOVATION OF ANI'S OPHTHALMOLOGY AND RETINA FRANCHISE FOR A MEANINGFUL IMPACT ON PATIENTS EXPERT RETINA AND UVEITIS SPECIALISTS WILL HELP SUPPORT THE GROWTH AND INNOVATION OF ANI'S OPHTHALMOLOGY AND RETINA FRANCHISE FOR A MEANINGFUL IMPACT ON PATIENTS

ANI PHARMACEUTICALS ANNOUNCES FORMATION OF FUTUREVISION ADVISORY COUNCIL TO HELP STRATEGICALLY GUIDE OPHTHALMOLOGY AND RETINA FRANCHISE

PATRICK D. WALSH STEPS DOWN AS CHAIRMAN AND WILL COMPLETE HIS CURRENT TERM AS BOARD MEMBER THOMAS J. HAUGHEY HAS BEEN UNANIMOUSLY ELECTED TO SERVE AS THE NEXT CHAIRMAN OF THE BOARD

ANI PHARMACEUTICALS ANNOUNCES BOARD TRANSITION

PRINCETON, N.J., NOV. 25, 2025 (GLOBE NEWSWIRE) -- ANI PHARMACEUTICALS, INC. (ANI OR THE COMPANY) (NASDAQ: ANIP) TODAY ANNOUNCED THAT NIKHIL LALWANI, CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE ON TUESDAY, DECEMBER 2, AT 2:00 P.M. ET.

ANI PHARMACEUTICALS TO PRESENT AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

PRINCETON, N.J., NOV. 11, 2025 (GLOBE NEWSWIRE) -- ANI PHARMACEUTICALS, INC. (ANI OR THE COMPANY) (NASDAQ: ANIP) TODAY ANNOUNCED THAT NIKHIL LALWANI, CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE  LONDON ON TUESDAY, NOVEMBER 18, AT 3:00 P.M.

ANI PHARMACEUTICALS TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE  LONDON

RECORD QUARTERLY NET REVENUES OF $227.8 MILLION, AN INCREASE OF 53.6% YEAR-OVER-YEAR PURIFIED CORTROPHIN GEL NET REVENUES OF $101.9 MILLION, AN INCREASE OF 93.8% YEAR-OVER-YEAR RECORD QUARTERLY ADJUSTED NON-GAAP EBITDA OF $59.6 MILLION, AN INCREASE OF 69.8% YEAR-OVER-YEAR DILUTED GAAP INCOME PER SHARE OF $1.13 AND RECORD ADJUSTED NON-GAAP DILUTED EARNINGS PER SHARE OF $2.04 RAISED 2025 TOTAL NET REVENUE GUIDANCE TO $854.0 MILLION TO $873.0 MILLION, ADJUSTED NON-GAAP EBITDA TO $221.0 MILLION TO $228.0 MILLION, AND ADJUSTED NON-GAAP DILUTED EARNINGS PER SHARE OF $ 7.37 TO $7.64 RARE DISEASE NET REVENUES EXPECTED TO REPRESENT APPROXIMATELY 50% OF TOTAL COMPANY NET REVENUES IN 2025, INCLUDING REVISED GUIDANCE FOR: PURIFIED CORTROPHIN GEL NET REVENUES OF $347.0 MILLION TO $352.0 MILLION, REPRESENTING YEAR-OVER-YEAR GROWTH OF 75% TO 78% , AND ILUVIEN (1) NET REVENUES OF $73.0 MILLION TO $77.0 MILLION PRINCETON, N.J., NOV. 07, 2025 (GLOBE NEWSWIRE) -- ANI PHARMACEUTICALS, INC. (NASDAQ: ANIP) (ANI OR THE COMPANY) TODAY ANNOUNCED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025.

ANI PHARMACEUTICALS REPORTS RECORD THIRD QUARTER 2025 FINANCIAL RESULTS AND RAISES 2025 GUIDANCE

PRINCETON, N.J., OCT. 24, 2025 (GLOBE NEWSWIRE) -- ANI PHARMACEUTICALS, INC. (ANI OR THE COMPANY) (NASDAQ: ANIP) TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE ITS THIRD QUARTER 2025 FINANCIAL RESULTS ON FRIDAY, NOVEMBER 7, 2025, PRIOR TO THE MARKET OPEN.

ANI PHARMACEUTICALS TO DISCUSS THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 7, 2025, AT 8:30 A.M. ET

PRESENTATION AT AAO 2025 PART OF ONGOING NEW DAY DATA DISSEMINATION AT MEDICAL MEETINGS PRESENTATION AT AAO 2025 PART OF ONGOING NEW DAY DATA DISSEMINATION AT MEDICAL MEETINGS

ANI PHARMACEUTICALS ANNOUNCES NEW DAY CLINICAL TRIAL RESULTS TO BE PRESENTED IN LATE-BREAKING ORAL PRESENTATION AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2025 MEETING

PRINCETON, N.J., AUG. 25, 2025 (GLOBE NEWSWIRE) -- ANI PHARMACEUTICALS, INC. (ANI OR THE COMPANY) (NASDAQ: ANIP) TODAY ANNOUNCED THAT NIKHIL LALWANI, PRESIDENT AND CHIEF EXECUTIVE OFFICER, ALONG WITH MEMBERS OF THE COMPANY'S EXECUTIVE LEADERSHIP TEAM WILL PRESENT AT TWO UPCOMING INVESTOR CONFERENCES AS FOLLOWS:

ANI PHARMACEUTICALS TO PRESENT AT UPCOMING INVESTOR CONFERENCES

BAUDETTE, MINN., AUG. 08, 2025 (GLOBE NEWSWIRE) -- ANI PHARMACEUTICALS, INC. (NASDAQ: ANIP) (ANI OR THE COMPANY) TODAY ANNOUNCED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025.

ANI PHARMACEUTICALS REPORTS RECORD SECOND QUARTER 2025 FINANCIAL RESULTS AND RAISES 2025 GUIDANCE

PRINCETON, N.J., AUG. 01, 2025 (GLOBE NEWSWIRE) -- ANI PHARMACEUTICALS, INC. (ANI OR THE COMPANY) (NASDAQ: ANIP) TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE ITS SECOND QUARTER 2025 FINANCIAL RESULTS ON FRIDAY, AUGUST 8, 2025, PRIOR TO THE MARKET OPEN.

ANI Pharmaceuticals, Inc.

ANIP

Price

Financial Reports

No items found.

Press Releases

ANI Pharmaceuticals, Inc.

ANIP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ANIP